Enanta Pharmaceuticals, Inc. Q2 FY2024 earnings call

• Enanta focused on advancing virology and immunology pipelines in 2024 to bring oral therapeutics to market.
• RSV programs: Zelicapavir in Phase II studies RSVPEDs (pediatric) and RSVHR (adults with high-risk RSV). EDP-323 in Phase IIa challenge study for RSV.
• Immunology program: Work on oral KIT inhibitor for chronic spontaneous urticaria, aiming to select a development candidate in Q4 2024 and launch second immunology program in 2024.
• Welcomed Matthew Kowalsky as Chief Legal Officer.
• Upcoming milestones: Report EDP-323 challenge study data in Q3 2024, zelicapavir pediatric study data in H2 2024, identify CSU clinical candidate in Q4 2024, and launch second immunology program in 2024.

For the fiscal second quarter ended March 31, 2024, total revenue was $17.1 million, consisting of royalty revenue from AbbVie's MAVYRET. This is compared to $17.8 million in the same period of 2023. Research and development expenses were $35.6 million in Q2 2024, down from $43.5 million in Q2 2023, primarily due to reduced costs from the COVID-19 program but offset by increased costs for RSV and immunology programs. General and administrative expense was $14.2 million in Q2 2024, up from $13.8 million in Q2 2023, mainly due to legal expenses from the patent infringement lawsuit against Pfizer. Net loss for the quarter was $31.2 million, or $1.47 per diluted common share.

• Updated R&D expense guidance: $125 million to $145 million. General and administrative expense guidance: $50 million to $60 million.
• Expect current cash and securities to support business and development programs through Q3 2027.
• Anticipate reporting EDP-323 challenge study data in Q3 2024, zelicapavir pediatric study data in H2 2024, identify CSU clinical candidate in Q4 2024, and launch second immunology program in 2024.

• Patent litigation risk: Ongoing lawsuit against Pfizer, with trial expected to end in late 2024, outcome uncertain.
• Pipeline execution risk: Potential for pipeline programs to not progress as expected or clinical trial results not meeting expectations.
• Market competition risk: Competition from other companies developing therapies for RSV and immunology indications.

Q: Regarding data viewing for RSVPEDs study and impact on RSVHR, A: Tara Kieffer explains RSVPEDs is pediatric proof-of-concept II期 study, first confirms safety and dose, then looks at virology endpoints, clinical endpoints also considered but mainly virology, no specific threshold, references Arc Bio's China III期 study.

Q: Clinical development strategy for immunology program and second immunology program, A: Jay Luly and Tara Kieffer explain candidate to be identified in Q4 2024, enter clinic, use serum tryptase as biomarker, plan to expand to other immunology targets.

Q: RSVHR study power and expectations, A: Jay Luly explains RSVHR is II期 proof-of-concept study powered for 50% symptom resolution reduction, high bar but clinically meaningful improvements like shortening symptom resolution time are key.

Q: Doses of EDP-323 in challenge study and patent litigation, A: Jay Luly explains testing 600mg daily and 600mg loading dose plus 200mg daily, patent litigation expected trial end of 2024.

Q: Differentiators of oral KIT inhibitor and other CSU therapies, A: Tara Kieffer explains KIT inhibitor aims to match/exceed monoclonal antibody efficacy with oral administration, compares to BTK inhibitors and sees potential in multiple indications like chronic inducible urticaria, eosinophilic esophagitis.